company background image
LYEL logo

Lyell Immunopharma NasdaqGS:LYEL Stock Report

Last Price

US$12.76

Market Cap

US$189.0m

7D

46.1%

1Y

-73.7%

Updated

08 Jun, 2025

Data

Company Financials +

Lyell Immunopharma, Inc.

NasdaqGS:LYEL Stock Report

Market Cap: US$189.0m

Lyell Immunopharma (LYEL) Stock Overview

A clinical-stage cell therapy company, develops chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. More details

LYEL fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

Risk Analysis

Makes less than USD$1m in revenue ($65K)

Highly volatile share price over the past 3 months compared to the US market

Currently unprofitable and not forecast to become profitable over the next 3 years

Shareholders have been diluted in the past year


LYEL Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

Lyell Immunopharma, Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Lyell Immunopharma
Historical stock prices
Current Share PriceUS$12.76
52 Week HighUS$53.50
52 Week LowUS$7.65
Beta-0.27
1 Month Change59.50%
3 Month Change-6.36%
1 Year Change-73.74%
3 Year Change-87.49%
5 Year Changen/a
Change since IPO-96.22%

Recent News & Updates

Recent updates

Lyell Immunopharma: Oversold And Poised For A Turning Point To Growth

Oct 25

Lyell Immunopharma: Testing The T-Cell Thesis With 2 Upcoming Data Catalysts

Apr 16

Companies Like Lyell Immunopharma (NASDAQ:LYEL) Are In A Position To Invest In Growth

Feb 23
Companies Like Lyell Immunopharma (NASDAQ:LYEL) Are In A Position To Invest In Growth

Companies Like Lyell Immunopharma (NASDAQ:LYEL) Are In A Position To Invest In Growth

Nov 09
Companies Like Lyell Immunopharma (NASDAQ:LYEL) Are In A Position To Invest In Growth

Analysts' Revenue Estimates For Lyell Immunopharma, Inc. (NASDAQ:LYEL) Are Surging Higher

Aug 29
Analysts' Revenue Estimates For Lyell Immunopharma, Inc. (NASDAQ:LYEL) Are Surging Higher

We Think Lyell Immunopharma (NASDAQ:LYEL) Can Afford To Drive Business Growth

Aug 11
We Think Lyell Immunopharma (NASDAQ:LYEL) Can Afford To Drive Business Growth

Lyell Immunopharma (NASDAQ:LYEL) Is In A Good Position To Deliver On Growth Plans

Dec 15
Lyell Immunopharma (NASDAQ:LYEL) Is In A Good Position To Deliver On Growth Plans

Lyell Immunopharma gets FDA nod to start phase 1 trial of its cancer therapy LYL845

Oct 06

Companies Like Lyell Immunopharma (NASDAQ:LYEL) Are In A Position To Invest In Growth

Sep 12
Companies Like Lyell Immunopharma (NASDAQ:LYEL) Are In A Position To Invest In Growth

News Flash: Analysts Just Made A Huge Upgrade To Their Lyell Immunopharma, Inc. (NASDAQ:LYEL) Forecasts

Aug 08
News Flash: Analysts Just Made A Huge Upgrade To Their Lyell Immunopharma, Inc. (NASDAQ:LYEL) Forecasts

Companies Like Lyell Immunopharma (NASDAQ:LYEL) Are In A Position To Invest In Growth

Apr 29
Companies Like Lyell Immunopharma (NASDAQ:LYEL) Are In A Position To Invest In Growth

We Think Lyell Immunopharma (NASDAQ:LYEL) Can Afford To Drive Business Growth

Dec 31
We Think Lyell Immunopharma (NASDAQ:LYEL) Can Afford To Drive Business Growth

Here's Why We're Not Too Worried About Lyell Immunopharma's (NASDAQ:LYEL) Cash Burn Situation

Sep 17
Here's Why We're Not Too Worried About Lyell Immunopharma's (NASDAQ:LYEL) Cash Burn Situation

Shareholder Returns

LYELUS BiotechsUS Market
7D46.1%4.5%1.8%
1Y-73.7%-9.3%12.6%

Return vs Industry: LYEL underperformed the US Biotechs industry which returned -9.3% over the past year.

Return vs Market: LYEL underperformed the US Market which returned 12.6% over the past year.

Price Volatility

Is LYEL's price volatile compared to industry and market?
LYEL volatility
LYEL Average Weekly Movement23.9%
Biotechs Industry Average Movement12.2%
Market Average Movement7.9%
10% most volatile stocks in US Market17.4%
10% least volatile stocks in US Market4.1%

Stable Share Price: LYEL's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: LYEL's weekly volatility has increased from 17% to 24% over the past year.

About the Company

FoundedEmployeesCEOWebsite
2018300Lynn Seelywww.lyell.com

Lyell Immunopharma, Inc., a clinical-stage cell therapy company, develops chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The company develops therapies using various approaches, such as c-Jun overexpression and NR4A3 gene knockout, to endow functional resistance to exhaustion; Epi-R to generate population of stem-like T cells with reduced exhaustion and improved proliferation and antitumor activity; CD62L positive enrichment to generate CAR T cells with enhanced antitumor activity; and Stim-R, a proprietary synthetic-cell mimetic. It is also developing IMPT-314, a dual-targeting CD19/CD20 CAR T-cell product candidate that is in Phase 1/2 clinical development for the treatment of patients with aggressive relapsed/refractory large B-cell non-Hodgkin lymphoma; and solid tumors program which is in preclinical trial targeting solid tumor indications.

Lyell Immunopharma, Inc. Fundamentals Summary

How do Lyell Immunopharma's earnings and revenue compare to its market cap?
LYEL fundamental statistics
Market capUS$188.95m
Earnings (TTM)-US$334.52m
Revenue (TTM)US$65.00k
2,907x
P/S Ratio
-0.6x
P/E Ratio

Is LYEL overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
LYEL income statement (TTM)
RevenueUS$65.00k
Cost of RevenueUS$0
Gross ProfitUS$65.00k
Other ExpensesUS$334.59m
Earnings-US$334.52m

Last Reported Earnings

Mar 31, 2025

Next Earnings Date

n/a

Earnings per share (EPS)-22.59
Gross Margin100.00%
Net Profit Margin-514,649.23%
Debt/Equity Ratio0%

How did LYEL perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/06/08 10:25
End of Day Share Price 2025/06/06 00:00
Earnings2025/03/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Lyell Immunopharma, Inc. is covered by 6 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jason ZemanskyBofA Global Research
Salveen RichterGoldman Sachs
Mitchell KapoorH.C. Wainwright & Co.